Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$127.69 USD

127.69
1,121,487

-0.12 (-0.09%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $127.70 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (66 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Zacks Equity Research

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Glaukos (GKOS) owing to its strategic alliances and a strong iStent product line.

Zacks Equity Research

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of regulatory approvals and strength in its TomoTherapy platform.

Zacks Equity Research

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, segmental weakness is a woe.

Trina Mukherjee headshot

3 Stocks to Bank on Rebounding Outpatient Home Health Industry

by Trina Mukherjee

Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE and USPH are well-poised to gain from the prospects.

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI), owing to its potential in the Peripheral Intervention arm and strong international foothold.

Zacks Equity Research

PerkinElmer's (PKI) COVID-19 Test Kit Part of Investigative Study

by Zacks Equity Research

PerkinElmer's (PKI) test kit, which is currently being used in an investigative study, is aimed at accelerating the vaccine development and treatments against COVID-19.

Zacks Equity Research

Here's Why You Should Retain Ecolab (ECL) Stock Right Now

by Zacks Equity Research

Ecolab (ECL) continues to gain traction for a solid product portfolio and cost-efficiency program. However, segmental weakness remains a woe.

Zacks Equity Research

Veeva Systems' (VEEV) Cloud Offerings Aid Drug Development

by Zacks Equity Research

Veeva Systems' (VEEV) Cloud applications help in simplifying and accelerating drug development on an industry-wide basis.

Zacks Equity Research

Ecolab (ECL) Launches Roach Control Device for Food Outlets

by Zacks Equity Research

Ecolab's (ECL) latest device is expected to help the restaurant industry efficiently protect their brand reputation and eliminate any business and public health risk.

Zacks Equity Research

Here's Why You Should Hold on to Avanos (AVNS) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Avanos (AVNS), owing to its strong product line and focus on its R&D.

Zacks Equity Research

LHC Group (LHCG) Forays Into Tucson Market With New Buyout

by Zacks Equity Research

LHC Group (LHCG) agrees to buy two Casa de la Luz provider locations to expand its hospice service in the Tucson market.

    Zacks Equity Research

    Here's Why You Should Invest in Integer Holdings (ITGR) Stock

    by Zacks Equity Research

    Integer Holdings (ITGR) continues to gain traction from portfolio management.

    Zacks Equity Research

    NextGen (NXGN) Implements API to Aid COVID-19 Vaccination

    by Zacks Equity Research

    NextGen's (NXGN) API is expected to address the unique and evolving reporting needs of various states as they administer the COVID-19 vaccine.

    Zacks Equity Research

    DVA vs. AMED: Which Stock Should Value Investors Buy Now?

    by Zacks Equity Research

    DVA vs. AMED: Which Stock Is the Better Value Option?

    Zacks Equity Research

    PerkinElmer (PKI) to Boost Immunodiagnostics Unit With Buyout

    by Zacks Equity Research

    PerkinElmer (PKI) enters into an agreement to acquire IDS, which will enable the former to grow its overall Diagnostics business, particularly its immunodiagnostics unit.

    Zacks Equity Research

    Masimo (MASI), Spacelabs Team Up to Enhance Patient Outcome

    by Zacks Equity Research

    Masimo's (MASI) extension of partnership with Spacelabs is expected to provide better patient outcomes with the accessibility of patient monitoring solutions.

    Zacks Equity Research

    Here's Why You Should Add Inogen (INGN) to Your Portfolio

    by Zacks Equity Research

    Investors continue to be optimistic about Inogen (INGN) on its direct-to-customer business model and a strong product portfolio.

    Zacks Equity Research

    BD's (BDX) First Self-Collection HPV Screening Assay Gets CE Mark

    by Zacks Equity Research

    BD's (BDX) industry-first CE marked self-collection claim for HPV screening enables greater access to testing for women.

    Zacks Equity Research

    Veeva (VEEV) Enhances Clinical Trial Management via Vault CTMS

    by Zacks Equity Research

    Veeva's (VEEV) Vault CTMS application is expected to aid global organizations to advance study execution while ensuring compliance.

    Zacks Equity Research

    PRA Health's (PRAH) New Solution to Speed Up Drug Development

    by Zacks Equity Research

    PRA Health's (PRAH) tokenization solution can help in the generation of enhanced evidence for drug development through Synoma.

    Zacks Equity Research

    Here's Why You Should Retain Change Healthcare (CHNG) Stock

    by Zacks Equity Research

    Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.

    Zacks Equity Research

    Here's Why You Should Retain Intuitive Surgical (ISRG) Now

    by Zacks Equity Research

    Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System. However, rise in production costs is a woe.

    Zacks Equity Research

    Here's Why You Should Add DaVita (DVA) to Your Portfolio Now

    by Zacks Equity Research

    Investor confidence is high on the DaVita (DVA) stock, courtesy of its solid prospects.

      Zacks Equity Research

      Zacks.com featured highlights include: Herbalife, DaVita, Apple, Century Communities and Repligen Corp

      by Zacks Equity Research

      Zacks.com featured highlights include: Herbalife, DaVita, Apple, Century Communities and Repligen Corp

      Tirthankar Chakraborty headshot

      5 of the Best Stocks to Buy Now for Striking Earnings Growth

      by Tirthankar Chakraborty

      Herbalife (HLF), DaVita (DVA), Apple (AAPL), Century Communities (CCS) & Repligen (RGEN) are the top stocks that flaunt attractive earnings growth at present.